



## Autolus Therapeutics to Participate in Upcoming Investor Conferences in September

August 28, 2019 at 4:05 PM EDT

LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in the following investor conferences in September:

- Dr. Christian Itin, chairman and chief executive officer, will present at the Wells Fargo 2019 Healthcare Conference in Boston on Wednesday, September 4 at 3:00 p.m. ET and will host one-on-one meetings with attendees. A live webcast of the presentation will be available on the investor relations section of Autolus' website at <https://www.autolus.com>. An archived replay will be available on the company's website for a period of 90 days after the conference.
- Dr. Itin will participate in a fireside chat at the Morgan Stanley 17<sup>th</sup> Annual Global Healthcare Conference in New York on Monday, September 9 at 9:20 a.m. ET and will host one-on-one meetings with attendees. A live audio webcast of the fireside chat will be available on the investor relations section of Autolus' website at <https://www.autolus.com>. An archived replay will be available on the company's website for a period of 90 days after the conference.
- Andrew Oakley, chief financial officer, will present at the H.C. Wainwright 21<sup>st</sup> Annual Global Investment Conference in New York on Tuesday, September 10 at 2:10 p.m. ET and will host one-on-one meetings with attendees.

### About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: <https://www.autolus.com>.

#### Investor contact:

Susan A. Noonan  
S.A. Noonan Communications  
+1-212-966-3650  
[susan@sanoonan.com](mailto:susan@sanoonan.com)

#### Media contacts:

Silvia Taylor  
Vice President, Corporate Affairs and Communications  
Autolus  
+1-240-801-3850  
[s.taylor@autolus.com](mailto:s.taylor@autolus.com)

Julia Wilson  
JW Communications  
+44 (0) 7818 430877  
[j.wilson@autolus.com](mailto:j.wilson@autolus.com)

Source: Autolus Therapeutics plc